Martens
Dr. Martens has reported FY’24 results that align with its guidance, although its U.S. performance fell short of expectations, impacting the group’s overall results. The iconic British footwear brand plans to focus on the U.S. market with targeted marketing and cost-saving initiatives in FY’25, aiming for a return to growth…
By Svea Herbst-Bayliss BOSTON (Reuters) -Investment firm Marathon Partners Equity Management is turning up the heat on Dr Martens by urging the British boot maker to detail planned expense cuts and to buy back stock, people familiar with the matter told Reuters. The increased pressure comes roughly two months after…
